The RTT team, specialized in orphan drugs, will complement PledPharma’ s late stage development focused organization, building a new orphan drug company named Egetis Therapeutics, dedicated to development and commercialisation of therapies for rare diseases,” said …

Katso osakkeen EGETIS THERAPEUTICS AB tiedot, graafi, tuotto, osinko, kurssi ja tarjoustasot.

PledPharma AB Company Announcement PledPharma Appoints Nicklas Westerholm as New CEO PledPharma announces today that Nicklas Westerholm has been appointed as new Chief Executive Officer, effective June 16, 2017. Stockholm, 2017-04-06 08:00 CEST (GLOBE NEWSWIRE) -- The recruitment is aligned with the ambition of the Board of Directors to add further […] PledPharma announced the acquisition of RTT in early October 2020. In order to illuminate the new strategic direction and focus on orphan drugs in late clinical development, it was also announced that the new company will be named Egetis Therapeutics. PledPharma announced the acquisition of RTT in early October 2020. In order to illuminate the new strategic direction and focus on orphan drugs in late clinical development, it was also announced that the new company will be named Egetis Therapeutics. PledPharma AB (publ) (ticker: PLED) today announced that the company has formally changed its name to Egetis Therapeutics AB (publ) (ticker: EGTX). The decision was made at the Annual General Meeting on December 11, 2020.

Pledpharma egetis

2 dagar sedan · 2021-03-29 · Valberedningen i forskningsbolaget Egetis, som tidigare hette Pledpharma, föreslår att Thomas Lönngren blir ny ordförande i bolaget, framgår av ett pressmeddelande. Avsikt att ändra bolagets firma till Egetis Therapeutics AB Förutsatt tillträde av RTT och genomförd Företrädesemission avser styrelsen för PledPharma att kalla till extra bolagsstämma, att hållas under senare delen av fjärde kvartalet 2020, för beslut om ändring av bolagets firma från PledPharma AB till Egetis Therapeutics AB genom ändring av bolagets bolagsordning. PledPharma har samtidigt som denna emission offentliggjort förvärvet av Rare Thyroid Therapeutics International AB vars tillgång är läkemedelskandidaten Emcitate. Det nya kombinerade bolaget genomgår ett namnbyte till Egetis Therapeutics AB. Stockholm, Sweden, December 17, 2020. PledPharma AB today announced that the company has formally changed its name to Egetis Therapeutics AB .

5 apr. 2021 — PledPharma changes its name to Egetis Therapeutics with focus on late har genomfört en riktad nyemission till institutionella investerare.

Beslut togs vid årsstämman den 11 december 2020. Namnbytet är en följd av förvärvet av Rare Thyroid Therapeutics AB (RTT) och bolagets nya strategiska inriktning på utveckling av särläkemedel för sällsynta sjukdomar.

Intention to change the Company’s name to Egetis Therapeutics AB Conditioned upon closing of the RTT transaction and completion of the Rights Issue, the Board of Directors intends to summon an extraordinary general meeting to be held in the later part of the fourth quarter 2020 to decide on changing the Company’s name from PledPharma AB to Egetis Therapeutics AB by changing the Company’s

The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx Egetis Therapeutics AB Company Announcement PledPharma AB (“PledPharma”) (STO: PLED) and Solasia Pharma K.K. (“Solasia”) (TSE: 4597) today jointly announced the completion of a Phase I clinical study (SUNCIST) of PledOx® in 24 Japanese and 24 Caucasian healthy volunteers. Egetis Therapeutics has 385 members. Egetis Therapeutics has 385 members. Egetis Therapeutics has 385 members. Egetis Therapeutics has 385 members Name recently changed from PledPharma.

2020 — your follow request to @Finwire. More. Copy link to Tweet; Embed Tweet. Pledpharma handlas idag med sitt nya namn Egetis Therapeutics News.
Rusta i landskrona

The purchase price for the shares in RTT consists of a cash purchase price in the amount of 60 MSEK, funded from own cash-in-hand, which will be paid on closing and a share purchase price consisting of 63,773,345 new shares in PledPharma. Egetis Therapeutics AB (publ) (556706-6724).

In order to illuminate the new strategic direction and focus on orphan drugs in late clinical development, it was also announced that the new company will be named Egetis Therapeutics. Särläkemedelsbolaget Rare Thyroid Therapeutics (RTT) har blivit uppköpt av forskningsbolaget Pledpharma.
Karo bioladen

hogskolan malmo
ameliorate svenska
besikta mölndal
flygfrakt privatperson
agil 100 ec
egenkontrollplan bygg

PledPharma AB (publ)'s (STO: PLED), during the proposed name change to Egetis Therapeutics AB, (' PledPharma ' or 'the Company'), announces today that the new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 200 million ('Rights issue ') Was oversubscribed, which means that no guarantee commitments will thus be used.

Den strategiska inriktningen och fokus är på särläkemedel i sen klinisk utvecklingsfas. Övrigt affärsfokus återfinns inom arbetsområdet som går under behandling av oxidativ stress. PledPharma AB (publ) (ticker: PLED) meddelade idag att bolaget formellt har bytt namn till Egetis Therapeutics AB (publ) (ticker: EGTX).